Expression and potential role of fas-associated phosphatase-1 in ovarian cancer

American Journal of Pathology

Volumn 158, Issue 4, 2001, Pages 1335-1344

  Meinhold Heerlein, Ivo ^a   Stenner Liewen, Frank ^a   Liewen, Heike ^a   Kitada, Shinichi ^a   Krajewska, Maryla ^a   Krajewski, Stanislaw ^a   Zapata, Juan M ^a   Monks, Anne ^b   Scudiero, Dominic A ^b   Bauknecht, Thomas ^c   Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ASSOCIATED PHOSPHATASE 1; MESSENGER RNA; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN TYROSINE PHOSPHATASE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CORRELATION FUNCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

EID: 0035067402     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64084-9     Document Type: Article

References (40)

1. The polypeptide encoded by the cDNA for human cell surface antigen fas can mediate apoptosis
2. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs
3. A protein tyrosine phosphatase that associates with Fas/APO-1 (CD95)
4. Negative regulation of Fas-mediated apoptosis by FAP-1 in human cancer cells
5. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis
6. Expression of Fap-1 (Fas-associated phosphatase) and resistance to Fas-mediated apoptosis in T cell lines derived from human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients
7. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity
8. Comparison of in vitro anticancer drug-screening data generated with tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines
9. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines
10. The National Cancer Institute Cancer Drug Discovery and Development
11. New colorimetric cytotoxicity assay for anticancer drug-screening
12. Differential effects of Bcl-2 on T and B cells in transgenic mice
13. A strategy for generating monoclonal antibodies against recombinant baculovirus-produced proteins: Application to the Bcl-2 oncoprotein
14. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease
15. Tissue microarrays for high-throughput molecular profiling of tumor specimens
16. Aminoalkylsilane-treated glass slides as support for in situ hybridization of keratin cDNAs to frozen tissue sections under varying fixation and pretreatment conditions
17. Immunohistochemical analysis of in vivo patterns of Bcl-X expression
18. Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines
19. Unequal death in T helper cell effectors: thl, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis
20. The molecular interaction of Fas and FAP-1: A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis
21. Characterization of FAP-1 expression and function in thyroid follicular cells
22. In vivo expression of soluble Fas and Fap-1: Possible mechanisms of Fas resistance in human hepatoblastomas
23. Immunohistochemical localization of FAP-1, an inhibitor of Fas-mediated apoptosis, in normal and neoplastic human tissues
24. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis
25. Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage
26. No evidence for involvement of mouse protein-tyrosine phosphatase-bas-like fas-associated phosphatase-1 in fas-mediated apoptosis
27. Functional interaction of Fas-associated phosphatase-1 (FAP-1) with p75 and their effect on NF-kB activation
28. Soluble tumor necrosis factor receptors and CA125 in serum as markers for epithelial ovarian cancer
29. Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer
30. Tumor necrosis factor and its receptors in human ovarian cancer Potential role in disease progression
31. Expression of Fas antigen in acute myeloid leukemia is associated with therapeutic response to chemotherapy
32. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions
33. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system
34. Thymineless death in colon carcinoma cells is mediated via fas signaling
35. A Fas-dependent Component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells
36. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
37. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines - A preliminary report
38. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
39. Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells
40. Structural modification of Fas C-terminal tripeptide and its effects on the inhibitory activity of Fas/FAP-1 binding